Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, combined with lenalidomide ± daratumumab, showed promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients. MagnetisMM-6 Phase 3 trial (NCT05623020) evaluated ELRA in dose level G (DLG), establishing its recommended phase 3 dose for further study.

Key Points:

• Research Problem/Question: Evaluate ELRA efficacy and safety in transplant-ineligible NDMM.
• Methodology: Phase 3, open-label, randomized study with DLG focusing on safety and preliminary efficacy.
• Key Findings: High response rates (ORR 91.9%) with manageable toxicities; frequent CRS (62.2%) and neutropenia (70.3%).
• Significance/Impact: Potential new treatment option for this patient population.

Conclusion:
Elranatamab combination therapies, particularly with lenalidomide, demonstrate robust efficacy and manageable safety profiles in transplant-ineligible newly diagnosed multiple myeloma patients, warranting further investigation in ongoing trials.

Authors:
Hang Quach, Luděk Pour, Sebastian Grosicki, Hanlon Sia, Jiri Minarik, Ja Min Byun, Cyrille Touzeau, Carmine Liberatore, Sharon Sullivan, Eric Leip, Eeman Shaikh, Andrea Viqueira, Meletios Dimopoulos.

Clinical Trial Registration Number: NCT05623020
DOI: 10.1200/JCO.2025.43.16_suppl.7504
Abstract#7504